The role of CDK inhibitors in breast cancer therapy

Joanna Huszno


Cyclin D1 and cyclin-dependent protein kinases CDK4/6 are part of RB-pathway which plays a very important role in the regulation of cell cycle progression and cell death. d-type cyclins associate with cdk4 and 6 to phosphorylate the Rb protein. Hyperphosphorylation of Rb promotes the release of the E2F family of transcription factors that then promotes entry into S phase through activation of key target genes. CDK inhibitors are proteins that suppress CDK-cyclin protein kinase activity in the G1 phase of the cell cycle and promote G1 arrest in response to environmental or intracellular signals. A literature search of these topics was performed through PubMed. Results from preclinical and early-stage clinical trials support the efficiency of CDK inhibitors such palbociclib, abemaciclib and ribociclib for the treatment of human cancers - including breast cancer. The first-in-class CDK4/6 inhibitor, which significantly extended PFS in combination with endocrine therapy in the first and subsequent lines of treatment for steroid receptor -positive, HER2-negative advanced breast cancer is Palbociclib. Other inhibitors (abemaciclib, ribociclib) are still in clinical trials and are a very promising group of drugs.


CDK inhibitors, Palbociclib, Abemaciclib, Ribociclib, Breast cancer

Full Text:



Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673–84.

Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;10:1973–79.

Gampenrieder SP, Rinnerthaler G, Greil R. Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future. Journal of Oncology.2013: 2013,1-12.

Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genes Dev. 1998;8:28-35.

Wang T, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.), 1994;369: 669-71.

Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin. E Mol Cell Biol 1997;17:453-59.

Mangini NS, Wesolowski R, Ramaswamy B, et al. A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. Ann Pharmacother. 2015;49(11):1252-60.

Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015;21(21):4760-6.

Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.

Finn RS, Dering J, Conklin D, et al. PD 0332991 a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.

Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res. 2010;16:1094-9.

Choi YJ, Li X, Hydbring P, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012; 22:438–51.

Musgrove EA, Caldon CE, Barraclough J, et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011; 11:558–572.

Trimarchi JM, Lees J A. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11–20.

Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004;9:95–104.

Sutherland RL, Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009;11:112.

Witkiewicz A, Cox DW, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes & Cancer. 2014;5:261–72.

A study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER/HER2- advanced breast cancer (PALOMA-2). National Cancer Institute at the National Institutes of Health Clinical Trials. Available at: [Accessed August 12, 2015].

Nicholas C. Turner, Jungsil Ro et al. PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J Clin Oncol. 2015; 33 (suppl; abstr LBA502).

Ziemke EK, Dosch JS, Maust JD, et al. Sensitivity of KRAS Mutant Colorectal Cancers to Combination Therapy that Co-Targets MEK and CDK4/6. Clin Cancer Res. 2015;22(2):405-14.

Vaughn DJ, Hwang WT, Lal P, et al. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2015 1;121(9):1463-8.

Altenburg JD, Farag SS. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015;24: 261-71.

Dubus P. CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS]. Med Sci (Paris). 2010;26(12):1023-5.

Tolaney SM, Rosen LS, Beeram M, et al. Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer. Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2014.

MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer. Available from

MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2015;33:(suppl; abstr TPS624).

Raub TJ, Wishart GN, Kulanthaivel P, et al. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Drug Metab Dispos. 2015;43(9):1360-71.

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain. Available from

Yadav V, Chen SH, Yue YG, et al. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Pharmacol Ther. 2015;149:139-49.

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer. Available from

Goldman JW, Shi P, Reck M, et al. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. Clin Lung Cancer. 2016;17 (1):80-4.

Infante JR, Shapiro G, Witteveen P, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. Journal of Clinical Oncology. 2014;32(15):2528.

Munster PN, Hamilton EP, Franklin C, et al. Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2– BC). Journal of Clinical Oncology. 2014:533.

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE). Available from

A pharmacodynamics pre-surgical study of LEE011 in early breast cancer patients (MONALEESA-1). Available from

Vidula N, Rugo HS. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clinical Breast Cancer, 2016;16:8-17.

Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer. (MONALEESA-2). Available from

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7). Available from

Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer. Available from

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma. Available from

LEE011 in Neuroendocrine Tumors of Foregut Origin. Available from

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. Available from


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the '' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013